iPill

Today, many addiction treatment providers still operate in a reactive model. They often do not know what is happening with a patient’s medication adherence until a missed visit, relapse, diversion issue, compliance concern, or crisis has already occurred. iPill is designed to change that by giving providers real-time visibility into medication use, patient behavior, adherence trends, and early signals that may call for intervention.

At the center of iPill is the iPill Adherence Ecosystem — a connected medtech and digital health platform that combines a secure at-home medication dispenser, patient mobile app, biometric authentication, video-supported dosing, tamper alerts, provider dashboard, adherence data, care-team notifications, and proactive clinical workflow support. The goal is simple: help providers move from guessing what happens between visits to knowing when a patient may need support.

This matters because addiction treatment providers are under pressure from every direction: staffing shortages, high patient churn, regulatory scrutiny, diversion risk, limited clinic capacity, and growing demand for remote care. iPill gives these organizations a way to modernize care without simply adding more labor. The platform is built to help clinics improve medication accountability, support safer take-home dosing, reduce operational burden, strengthen documentation, and identify opportunities for earlier patient engagement.

For patients, iPill can help reduce the burden of frequent clinic visits while keeping them connected to their treatment team and support network. For providers, it creates a more scalable care model with better visibility, stronger workflows, and potential revenue opportunities tied to remote monitoring and proactive care services. In other words, iPill is not just building a device — it is building infrastructure for a more connected, accountable, and proactive addiction treatment system.

iPill’s business model is built around recurring B2B provider subscriptions. Clinics pay for access to the dispenser, software, analytics, monitoring tools, setup, and platform support. This model is designed to create predictable recurring revenue while giving healthcare providers a technology solution that can support both better care delivery and stronger clinic economics.

The initial market focus is Opioid Treatment Programs, MAT/MOUD providers, addiction treatment organizations, behavioral health providers, and healthcare systems managing patients on controlled or high-risk medications. These are high-need, high-pressure settings where the cost of poor adherence, patient drop-off, diversion, and delayed intervention can be significant.

iPill is led by a team with deep experience across medicine, FDA-regulated medical devices, healthcare operations, addiction treatment, revenue cycle strategy, product development, law, and commercialization.  The company is also supported by an advisory and board network with experience in technology investing, venture capital, FDA regulation, law enforcement, pain medicine, and DEA leadership. That combination gives iPill a strong foundation across the clinical, regulatory, operational, and commercial areas needed to build in a complex healthcare market.

The bigger vision is clear: addiction treatment is moving away from outdated, reactive care and toward connected, data-driven, proactive support. iPill is positioning itself to be part of that transformation — helping providers deliver safer care, helping patients stay connected, and helping the healthcare system move toward a future where medication adherence is visible, actionable, and intelligently supported.